TORONTO, July 26, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX”
or the “Company”) (CSE:MPX) (OTC:MPXEF) today announced the Company will issue its fiscal 2018 full-year results
release on July 30, 2018 after markets close.
The Company will host a conference call on Tuesday, July 31, 2018 at 10:00 AM Eastern Time.
|
Participant Dial-In Numbers: |
Toll-Free: 1-800-289-0438 |
Toll / International: 1-323-794-2423 |
Participants should request the MPX earnings call or
provide confirmation code 8723616 |
|
Investors are invited to listen via webcast available on the MPX investor section of the Company’s website at
https://mpxbioceutical.com/investors/. Please visit the website 15 minutes prior to the call to
register, download, and install any necessary audio software. For interested individuals unable to join the conference call, a
replay of the call will be available through August 7, 2018, at 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671
(International). Participants must use the following code to access the replay of the call: 8723616. The online archive of the
webcast will be available on the investor section of the Company’s website for 30 days following the call.
W. Scott Boyes, Chairman, President and Chief Executive Officer of MPX, David McLaren, Chief Financial Officer,
and Beth Stavola, Chief Operating Officer, will be answering shareholder questions at the conclusion of the call.
To be added to the distribution list, please email MPX@kcsa.com with “MPX” in the subject line.
About MPX Bioceutical Corporation
MPX, through its wholly-owned subsidiaries in the U.S., provides substantial management, staffing, procurement,
advisory, financial, real estate rental, logistics and administrative services to three medicinal cannabis enterprises in Arizona
operating under the Health for Life (dispensaries) and the award-winning Melting Point Extracts (high-margin concentrates
wholesale) brands. The successful Health for Life brand operates in the rapidly growing Phoenix Metropolitan Statistical
Area. With the acquisition of The Holistic Center, MPX added another operating medical cannabis enterprise to its footprint
in Arizona.
GreenMart of Nevada NLV, LLC (“GreenMart NV”) is an award winning licensed cultivation,
production and wholesale business, licensed for both the medical and “adult use” sectors in Las Vegas, Nevada, and is already
selling wholesale into the Nevada medical cannabis market. GreenMart NV has also optioned suitable locations and intends to enter
the higher-margin retail arena by applying for at least two dispensary licenses in the Las Vegas market which will operate under
the “Health for Life” brand.
In Massachusetts, MPX is building out and will operate a cultivation and production facility as well as up to
three dispensaries and manages three full service dispensaries and one producer in Maryland.
In Canada, MPX has acquired Canveda, which has received its cultivation license from Health Canada, will operate
a cultivation and production facility in Peterborough, Ontario. The Company also leases a property in Owen Sound, Ontario, for
which an application to Health Canada has been made for a cannabis production and sales license. In addition, the Company will
continue its efforts to develop its legacy nutraceuticals business.
Cautionary Statement Regarding Forward-Looking Information
This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not
historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results,
performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements.
Forward-looking statements in this news release include, but are not limited to, MPX’s objectives and intentions.
Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are
subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ
materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to:
general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory,
political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional
risks set out in MPX’s public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although MPX
believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should
not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such
events will occur in the disclosed time frames or at all. Except where required by law, MPX disclaims any intention or obligation
to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
On behalf of the Board of Directors
MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation)
W. Scott Boyes, Chairman, President and CEO
For further information, please contact:
MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation)
W. Scott Boyes, Chairman, President and CEO
T: +1-416-840-3725
info@mpxbioceutical.com
www.mpxbioceutical.com
Media Contact:
Anne Donohoe
KCSA Strategic Communications
212-896-1265
adonohoe@kcsa.com
Investor Contact:
Phil Carlson / Elizabeth Barker
KCSA Strategic Communications
212-896-1233 / 212-896-1203
pcarlson@kcsa.com / ebarker@kcsa.com